FHTX · Foghorn Therapeutics Inc.
$4.84
-0.23 (-4.54%)
At close · Jul 24
Market Cap
$284.76M
Shares
58.71M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$30.91M
+36.8%
FY2025
Net Income
-$74.28M
+14.2%
FY2025
Operating Margin
-279.49%
+174.8pp
FY2025
Diluted EPS
-$1.18
+25.3%
FY2025
Operating Cash Flow
-$86.1M
+14.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $28.22M | $30.91M | $22.6M | $34.16M | $19.23M | $1.32M | $430K | — | |
| $82.1M | $85.47M | $94.53M | $109.69M | $105.62M | $80.33M | $57.72M | $44.36M | |
| $26.89M | $27.55M | $28.36M | $32.37M | $30.75M | $21.73M | $11.25M | $6.72M | |
| $2.74M | $3.33M | $3.12M | $3.45M | $3.32M | $3.23M | $1.33M | $693K | |
| $113.27M | $117.3M | $125.29M | $142.06M | $136.37M | $102.05M | $68.96M | $51.08M | |
| -$85.05M | -$86.39M | -$102.68M | -$107.91M | -$117.14M | -$100.73M | -$68.53M | -$51.08M | |
| — | -279.49% | -454.31% | -315.93% | -609.2% | -7637.15% | -15937.44% | — | |
| -$82.31M | -$83.06M | -$99.56M | -$104.46M | -$113.82M | -$97.51M | -$67.2M | -$50.39M | |
| $426K | — | — | — | — | $1.91M | $979K | $540K | |
| $9.73M | $12.11M | $16.06M | $13.71M | $8.26M | -$586K | -$269K | -$44K | |
| — | — | -$86.62M | -$94.2M | -$108.88M | — | — | — | |
| — | $0 | $0 | $4.23M | $0 | — | $0 | $0 | |
| -$75.32M | -$74.28M | -$86.62M | -$98.43M | -$108.88M | -$101.32M | -$68.8M | -$51.13M | |
| — | -240.33% | -383.24% | -288.17% | -566.27% | -7681.58% | -16000% | — | |
| -$75.47M | -$74.39M | -$85.66M | -$95.27M | -$112.86M | -$101.32M | -$68.81M | -$51.13M | |
| USD/shares | — | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | — |
| USD/shares | — | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | -$6.23 | — |
| shares | — | 62.98M | 54.9M | 41.97M | 41.59M | 37.17M | 11.05M | 4.19M |
| shares | — | 62.98M | 54.9M | 41.97M | 41.59M | 37.17M | 11.05M | 4.19M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| The Segment | $30,909,000 | $22,602,000 | $34,155,000 |
Key facts
CIK
1822462
CUSIP
344174107
13F (30d)
13 filings
13 filers
Visit website
Investor relations